A Texas Depo-Provera lawsuit filed in the Multi-District Litigation (MDL) claims a brain hemorrhage took the Plaintiff’s life.
Texas Depo-Provera patient, AP, lived in Texas but spent significant years in Minnesota. She received Depo-Provera injections from 2006 to 2012 while residing in Minnesota. Her healthcare providers continued administering Depo-Provera until her death in 2024. AP and her doctors relied on defendants’ claims that Depo-Provera was safe for contraception.
On October 5, 2024, friends found AP deceased at her home. AP had turned forty-seven only weeks before her death. An autopsy showed a meningioma in the left posterior cranial fossa.
The tumor compressed and invaded her left cerebellar hemisphere. The tumor caused hemorrhaging into subarachnoid and subdural spaces around her brainstem. The medical examiner listed posterior cranial fossa hemorrhage from meningioma as her cause of death.
AP never knew she had a meningioma during her lifetime. Doctors diagnosed the tumor for the first time at autopsy. Plaintiff alleges AP could not have discovered the connection between Depo-Provera and her tumor before death. AP’s next of kin claim funeral expenses and loss of support from her death.
Click here for our additional information on claiming Depo-Provera compensation in Texas.
Understanding Depo-Provera Meningioma Hemorrhage
Depo-Provera meningioma hemorrhage involves bleeding from a hormone-sensitive brain tumor linked to prolonged Depo-Provera use. Depo-Provera contains medroxyprogesterone acetate, a synthetic hormone that interacts with progesterone receptors in the brain’s protective layers. This hormonal activity can stimulate tumor cell growth in patients predisposed to meningiomas.
Over time, a hormone-sensitive meningioma may enlarge rapidly. As the tumor grows, it can disrupt nearby blood vessels and increase intracranial pressure. Weakened vessels inside or around the tumor can rupture suddenly, causing a Depo-Provera meningioma hemorrhage.
This hemorrhage often occurs without warning. Patients may experience sudden headaches, vomiting, vision loss, or seizures before losing consciousness. A severe Depo-Provera meningioma hemorrhage can cause irreversible brainstem compression and death within hours.
Medical imaging, such as MRI or CT scans, often confirms the presence of both tumor and hemorrhage. Neuropathology reports after surgery or autopsy can show hormone-sensitive tumor cells linked to Depo-Provera use.
Scientific literature documents increased meningioma risk among women using injectable progesterone contraceptives for more than three years. These findings support the growing number of Depo-Provera meningioma hemorrhage lawsuits filed in U.S. courts.